Citadel Advisors
ARQT icon

Citadel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Citadel Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Sell
56,900
-55,100
-49% -$1.41M ﹤0.01% 6981
2025
Q4 		$3.25M Buy
112,000
+46,600
+71% +$1.19M ﹤0.01% 5020
2025
Q3 		$1.23M Sell
65,400
-17,900
-21% -$282K ﹤0.01% 7092
2025
Q2 		$1.17M Sell
83,300
-15,600
-16% -$219K ﹤0.01% 6740
2025
Q1 		$1.55M Buy
98,900
+38,500
+64% +$542K ﹤0.01% 6033
2024
Q4 		$841K Sell
60,400
-29,300
-33% -$321K ﹤0.01% 7411
2024
Q3 		$834K Buy
89,700
+9,400
+12% +$92.8K ﹤0.01% 7222
2024
Q2 		$747K Sell
80,300
-4,700
-6% -$42.5K ﹤0.01% 7218
2024
Q1 		$842K Buy
85,000
+75,100
+759% +$560K ﹤0.01% 7295
2023
Q4 		$32K Sell
9,900
-1,500
-13% -$4.08K ﹤0.01% 12214
2023
Q3 		$60.5K Sell
11,400
-27,000
-70% -$230K ﹤0.01% 11518
2023
Q2 		$366K Buy
38,400
+20,700
+117% +$230K ﹤0.01% 8608
2023
Q1 		$195K Buy
17,700
+5,000
+39% +$72.3K ﹤0.01% 10236
2022
Q4 		$188K Buy
+12,700
New +$222K ﹤0.01% 10236
2022
Q3 		– Sell
-17,900
Closed -$381K – 12560
2022
Q2 		$381K Sell
17,900
-17,800
-50% -$365K ﹤0.01% 9245
2022
Q1 		$688K Buy
35,700
+17,300
+94% +$293K ﹤0.01% 8615
2021
Q4 		$382K Buy
18,400
+9,900
+116% +$197K ﹤0.01% 10334
2021
Q3 		$203K Sell
8,500
-7,600
-47% -$173K ﹤0.01% 11956
2021
Q2 		$439K Buy
+16,100
New +$453K ﹤0.01% 10347

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's ARQT Position: Q1 2026 in Review

Citadel Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 90% in Q1 2026, selling an estimated $3.56M and leaving 15,606 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #10004.

Citadel Advisors first reported a position in ARQT in Q1 2020 and has held it in 24 quarters since. The position peaked at $28.2M in Q3 2024. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Citadel Advisors held 15,606 shares of Arcutis Biotherapeutics worth $368K as of Q1 2026.
  • Citadel Advisors sold 139,552 Arcutis Biotherapeutics shares in Q1 2026, an estimated $3.56M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10004 holding.
  • Citadel Advisors first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Arcutis Biotherapeutics position peaked at $28.2M in Q3 2024.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.